The results suggest the two-edged nature of sirtuins: whereas certain isoforms (e.g., SIRT5) defend malignant cells, thereby undermining therapy, others, such as SIRT2, are involved in tissue-specific protection without promoting tumor survival. The gene discussed is SIRT2; the disease is neoplasm.